Visa Cl A (V) Valuation Rose While First Financial Bank – Trust Division Decreased Its Holding by $1.49 Million; Barclays Plc Raised Its Meridian Bioscience (VIVO) Holding by $303,632 as Shares Rose

May 23, 2018 - By Richard Conner

Visa Inc. (NYSE:V) Logo

Barclays Plc increased its stake in Meridian Bioscience Inc (VIVO) by 2711% based on its latest 2017Q4 regulatory filing with the SEC. Barclays Plc bought 21,688 shares as the company’s stock rose 1.05% while stock markets declined. The institutional investor held 22,488 shares of the in vitro & in vivo diagnostic substances company at the end of 2017Q4, valued at $315,000, up from 800 at the end of the previous reported quarter. Barclays Plc who had been investing in Meridian Bioscience Inc for a number of months, seems to be bullish on the $616.11M market cap company. The stock increased 0.52% or $0.07 during the last trading session, reaching $14.55. About 27,466 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since May 23, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.

First Financial Bank – Trust Division decreased its stake in Visa Inc Cl A (V) by 15.71% based on its latest 2017Q4 regulatory filing with the SEC. First Financial Bank – Trust Division sold 13,044 shares as the company’s stock rose 4.18% while stock markets declined. The institutional investor held 69,985 shares of the business services company at the end of 2017Q4, valued at $7.98M, down from 83,029 at the end of the previous reported quarter. First Financial Bank – Trust Division who had been investing in Visa Inc Cl A for a number of months, seems to be less bullish one the $291.82 billion market cap company. The stock decreased 0.32% or $0.42 during the last trading session, reaching $130.29. About 1.30 million shares traded. Visa Inc. (NYSE:V) has risen 31.98% since May 23, 2017 and is uptrending. It has outperformed by 20.43% the S&P500.

First Financial Bank – Trust Division, which manages about $606.39M US Long portfolio, upped its stake in Vanguard (VTV) by 3,214 shares to 152,030 shares, valued at $16.16M in 2017Q4, according to the filing. It also increased its holding in Ishares (QUAL) by 5,705 shares in the quarter, for a total of 174,824 shares, and has risen its stake in Vanguard (VNQ).

Investors sentiment increased to 1.05 in 2017 Q4. Its up 0.05, from 1 in 2017Q3. It increased, as 55 investors sold V shares while 605 reduced holdings. 141 funds opened positions while 552 raised stakes. 1.61 billion shares or 1.83% less from 1.64 billion shares in 2017Q3 were reported. Moreover, Drexel Morgan & has 0.34% invested in Visa Inc. (NYSE:V). Next Century Growth Investors Lc reported 0.38% in Visa Inc. (NYSE:V). Leavell Invest Mgmt reported 0.95% stake. Usca Ria Ltd Liability Corporation accumulated 0.54% or 43,168 shares. 32,834 were reported by Goelzer Invest Management. Pittenger & Anderson reported 0.99% stake. Boston Family Office Ltd Limited Liability Company stated it has 0.7% of its portfolio in Visa Inc. (NYSE:V). Perkins Coie Tru Commerce holds 25,912 shares or 1.48% of its portfolio. Putnam Invs Lc reported 5.27 million shares or 1.34% of all its holdings. Tokio Marine Asset Management Limited reported 10,596 shares or 0.18% of all its holdings. Richard C Young Com invested 1.84% of its portfolio in Visa Inc. (NYSE:V). Retirement Systems Of Alabama holds 0.66% or 1.20M shares in its portfolio. Factory Mutual Insurance holds 1.04% in Visa Inc. (NYSE:V) or 871,700 shares. Assetmark owns 10,096 shares. Park Avenue Ltd Liability Com has 0.22% invested in Visa Inc. (NYSE:V).

Analysts await Visa Inc. (NYSE:V) to report earnings on July, 19. They expect $1.10 earnings per share, up 27.91% or $0.24 from last year’s $0.86 per share. V’s profit will be $2.46B for 29.61 P/E if the $1.10 EPS becomes a reality. After $1.11 actual earnings per share reported by Visa Inc. for the previous quarter, Wall Street now forecasts -0.90% negative EPS growth.

Since December 13, 2017, it had 0 insider buys, and 5 selling transactions for $12.69 million activity. $5.65 million worth of Visa Inc. (NYSE:V) shares were sold by MAHON TULLIER KELLY. The insider Biggar Lynne sold 1,712 shares worth $205,440. 6,220 shares valued at $707,561 were sold by MATSCHULLAT ROBERT W on Wednesday, December 13. Another trade for 38,500 shares valued at $5.06M was sold by MCINERNEY RYAN.

More recent Visa Inc. (NYSE:V) news were published by: Seekingalpha.com which released: “Visa: Next Stop $135” on April 27, 2018. Also Seekingalpha.com published the news titled: “Is It Too Late To Buy Visa Stock?” on May 17, 2018. 247Wallst.com‘s news article titled: “Can Visa Deliver Another Earnings Beat?” with publication date: April 25, 2018 was also an interesting one.

Among 43 analysts covering Visa Inc. (NYSE:V), 34 have Buy rating, 0 Sell and 9 Hold. Therefore 79% are positive. Visa Inc. had 131 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Outperform” on Thursday, October 26. The firm has “Outperform” rating by Wells Fargo given on Thursday, October 22. DZ Bank downgraded the shares of V in report on Wednesday, January 24 to “Hold” rating. On Friday, July 22 the stock rating was maintained by Stifel Nicolaus with “Buy”. Cowen & Co maintained Visa Inc. (NYSE:V) on Friday, July 21 with “Buy” rating. The firm has “Buy” rating by Susquehanna given on Thursday, December 28. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, February 3. As per Wednesday, August 23, the company rating was maintained by KeyBanc Capital Markets. Guggenheim downgraded Visa Inc. (NYSE:V) on Tuesday, October 25 to “Neutral” rating. UBS maintained Visa Inc. (NYSE:V) on Tuesday, October 25 with “Buy” rating.

Since February 7, 2018, it had 2 insider purchases, and 0 sales for $28,784 activity. 1,000 shares were bought by Rice John McCune Jr., worth $14,750 on Wednesday, February 7.

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. Piper Jaffray maintained the shares of VIVO in report on Thursday, January 25 with “Sell” rating. The firm has “Sell” rating given on Thursday, October 19 by Piper Jaffray. Robert W. Baird maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) on Thursday, October 19 with “Hold” rating. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Hold” rating given on Thursday, September 10 by Canaccord Genuity. Robert W. Baird maintained it with “Hold” rating and $16.0 target in Thursday, January 25 report. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Neutral” rating given on Monday, March 21 by Hilliard Lyons. The firm has “Sell” rating given on Thursday, September 21 by Piper Jaffray. Canaccord Genuity maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) rating on Thursday, January 25. Canaccord Genuity has “Hold” rating and $16.0 target. As per Monday, March 28, the company rating was upgraded by Hilliard Lyons. The firm has “Sell” rating given on Thursday, July 27 by Piper Jaffray.

Visa Inc. (NYSE:V) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>